Radiomitigating pharmaceutical formulations

US9840483B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9840483-B2
Application numberUS-201615094192-A
CountryUS
Kind codeB2
Filing dateApr 8, 2016
Priority dateMay 7, 2013
Publication dateDec 12, 2017
Grant dateDec 12, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure relates to compounds of Formula (I) and (II), compositions containing the compounds (alone or in combination with other agents), and their use to prevent, mitigate or treat a) damage induced by ionizing radiation, b) inflammation or c) cancer.

First claim

Opening claim text (preview).

We claim: 1. A method of mitigating an effect of ionizing radiation on a cell, organ, tissue, or organism, comprising contacting the cell, organ, tissue, or organism with a compound having the structure of Formula II: wherein: Y 1 and Y 2 taken together with X form: and wherein: X is N; G is selected from N or —C(H)—; Z is absent or selected from substituted or unsubstituted alkyl, heteroalkyl, alkenyl, or alkynyl; R 4 is absent or selected from substituted or unsubstituted aryl; and R 5 and R 6 are each independently absent or lower alkyl. 2. The method of claim 1 , wherein G is N and R 4 is selected from phenyl, 4-fluorophenyl and 3-chlorophenyl. 3. The method of claim 1 , wherein Z is absent. 4. The method of claim 1 , wherein Z is prop-2-en-1-yl and R 4 is phenyl. 5. The method of claim 1 , wherein the compound is selected from the group consisting of compounds 1, 2, 3, 4, 7, 8, 9, and 10 of Table 1. 6. The method of claim 1 , wherein the compound has the structure: 7. The method of claim 1 , wherein the organism is a mammal. 8. A method of treating inflammation in an organism, comprising administering to the organism a compound having the structure of Formula II: wherein: Y 1 and Y 2 taken together with X form: and wherein: X is N; G is selected from N or —C(H)—; Z is absent or selected from substituted or unsubstituted alkyl, heteroalkyl, alkenyl, or alkynyl; R 4 is absent or selected from substituted or unsubstituted aryl; and R 5 and R 6 are each independently absent or lower alkyl. 9. The method of claim 8 , wherein G is N and R 4 is selected from phenyl, 4-fluorophenyl and 3-chlorophenyl. 10. The method of claim 8 , wherein Z is absent. 11. The method of claim 8 , wherein Z is prop-2-en-1-yl and R 4 is phenyl. 12. The method of claim 8 , wherein the compound is selected from the group consisting of compounds 1, 2, 3, 4, 7, 8, 9, and 10 of Table 1. 13. The method of claim 8 , wherein the compound has the structure: 14. The method of claim 8 , wherein the organism is a human. 15. A method of treating lung cancer in an organism, comprising administering to the organism a compound having the structure of Formula II: wherein: Y 1 and Y 2 taken together with X form: and wherein: X is N; G is selected from N or —C(H)—; Z is absent or selected from substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl; R 4 is absent or selected from substituted or unsubstituted aryl; and R 5 and R 6 are each independently absent or lower alkyl. 16. The method of claim 15 , wherein G is N and R 4 is selected from phenyl, 4-fluorophenyl and 3-chlorophenyl. 17. The method of claim 15 , wherein Z is absent. 18. The method of claim 15 , wherein Z is prop-2-en-1-yl and R 4 is phenyl. 19. The method of claim 15 , wherein the compound is selected from the group consisting of compounds 1, 2, 3, 4, 8, 9, and 10 of Table 1. 20. The method of claim 15 , wherein the compound has the structure: 21. The method of claim 13 , wherein the organism is a human.

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • Free radical scavengers or antioxidants · CPC title

  • Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

  • attached in position 3 · CPC title

  • Sulfur atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9840483B2 cover?
The present disclosure relates to compounds of Formula (I) and (II), compositions containing the compounds (alone or in combination with other agents), and their use to prevent, mitigate or treat a) damage induced by ionizing radiation, b) inflammation or c) cancer.
Who is the assignee on this patent?
Univ California
What technology area does this patent fall under?
Primary CPC classification C07D295/26. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).